Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy

International Journal of Laboratory Hematology

Volumn 31, Issue 4, 2009, Pages 468-470

  Tsutsumi, Y ^a   Ichiki, K ^a   Shiratori, S ^a   Kawamura, T ^a   Tanaka, J ^b   Asaka, M ^c   Imamura, M ^b   Masauzi, N ^a  

^a Hakodate Municipal Hospital   (Japan)

^b Department of Hematology and Oncology ^*  (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS ANTIBODY; VIRUS RNA;

ANTIBODY TITER; CANCER CHEMOTHERAPY; DRUG EFFECT; HEPATITIS C VIRUS; HUMAN; LARGE CELL LYMPHOMA; LETTER; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 67651098723     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2008.01034.x     Document Type: Letter

References (8)

1. Aksoy S., Abali H., Kilickap S., Erman M. Kars A. (2006) Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clinical & Laboratory Haematology 28, 211 214.
2. Lake-Bakaar G., Dustin L., McKeating J., Newton K., Freeman V. Frost S.D.W. (2007) Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 109, 845 846.
3. Mele A., Pulsoni A., Bianco E., Musto P., Szklo A., Sanpaolo M.G., Iannitto E., De Renzo A., Martino B., Liso V., Andrizzi C., Pusterla S., Dore F., Maresca M., Rapicetta M., Marcucci F., Mandelli F. Franceschi S. (2003) Hepatitis C virus and B-cell non-Hodgkin's lymphomas: an Italian multicenter case-control study. Blood 102, 996 999.
4. de Sanjose S., Nieters A., Goedert J.J., Domingo-Domenech E., Fernandez de Sevilla A., Bosch R., Herrera P., Domingo A., Petit J., Bosch X. Kallinowski B. (2004) Role of hepatitis C virus infection in malignant lymphoma in Spain. International Journal of Cancer 111, 81 85.
5. Takeshita M., Sakai H., Okamura S., Higaki K., Oshiro Y., Uike N., Yamamoto I., Shimamatsu K. Muranaka T. (2006) Prevalence of hepatitis C virus infection in cases of B-cell lymphoma in Japan. Histopathology 48, 189 198.
6. Takeuchi T., Katsume A., Tanaka T., Abe A., Inoue K., Tsukiyama-Kohara K., Kawaguchi R., Tanaka S. Kohara M. (1999) Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 116, 636 642. (Pubitemid 29106771)
7. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M. Masauzi N. (2005) Reactivation of hepatitis B virus with rituximab. Expert Opinion on Drug Safety 4, 599 608.
8. Vigna-Perez M., Hernández-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C. González-Amaro R. (2006) Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Research & Therapy 8, R83 R92.